Georgian medical news · 2025
SERUM BIOMARKERS FOR EARLY SEVERITY STRATIFICATION IN ACUTE PANCREATITIS: A NARRATIVE REVIEW.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baltabayeva A, Shakeev K, Klyuyev D, Ogizbayeva A
Аннотация
BACKGROUND: Acute pancreatitis (AP) is an inflammatory disorder with an unpredictable course, ranging from mild self-limiting forms to necrotizing pancreatitis with multiple organ failure. Despite advances in imaging and scoring systems, early severity prediction remains a major challenge. Circulating biomarkers have gained attention as tools for improving diagnostic precision and patient risk stratification.
AIM: To summarize and сcomprehensively evaluate current literature on serum biomarkers used or proposed for predicting acute pancreatitis severity and complications, and to determine their prognostic and clinical value for potential integration into existing scoring systems.
MATERIALS AND METHODS: A comprehensive search of PubMed, Scopus, Google Scholar, and The Cochrane Library identified retrospective and prospective studies assessing diagnostic and prognostic performance of biomarkers - C-reactive protein (CRP), procalcitonin, lipase, angiopoietins (ANG-1, ANG-2), fibrinogen-like proteins (FGL1, FGL2) and interleukins (IL-6, IL-38).
RESULTS: Classical biomarkers (CRP, procalcitonin, nitrogen, protein, and electrolyte indicators) retain diagnostic relevance but show limited specificity. Emerging markers (angiopoietin-2, FGL1, FGL2, cytokines, D-dimer) demonstrate higher sensitivity and prognostic accuracy for organ failure and necrosis, though clinical use remains limited by cost and lack of multicenter validation.
CONCLUSION: Serum biomarkers hold significant potential for improving early severity prediction in AP. Integrating novel and traditional markers with scoring systems may enhance diagnostic accuracy and guide timely intervention. Further multicenter studies are required for clinical validation and implementation.
AIM: To summarize and сcomprehensively evaluate current literature on serum biomarkers used or proposed for predicting acute pancreatitis severity and complications, and to determine their prognostic and clinical value for potential integration into existing scoring systems.
MATERIALS AND METHODS: A comprehensive search of PubMed, Scopus, Google Scholar, and The Cochrane Library identified retrospective and prospective studies assessing diagnostic and prognostic performance of biomarkers - C-reactive protein (CRP), procalcitonin, lipase, angiopoietins (ANG-1, ANG-2), fibrinogen-like proteins (FGL1, FGL2) and interleukins (IL-6, IL-38).
RESULTS: Classical biomarkers (CRP, procalcitonin, nitrogen, protein, and electrolyte indicators) retain diagnostic relevance but show limited specificity. Emerging markers (angiopoietin-2, FGL1, FGL2, cytokines, D-dimer) demonstrate higher sensitivity and prognostic accuracy for organ failure and necrosis, though clinical use remains limited by cost and lack of multicenter validation.
CONCLUSION: Serum biomarkers hold significant potential for improving early severity prediction in AP. Integrating novel and traditional markers with scoring systems may enhance diagnostic accuracy and guide timely intervention. Further multicenter studies are required for clinical validation and implementation.